As of Aug 14
| +0.44 / +4.29%|
The 6 analysts offering 12-month price forecasts for Viking Therapeutics Inc have a median target of 14.50, with a high estimate of 15.00 and a low estimate of 13.00. The median estimate represents a +35.64% increase from the last price of 10.69.
The current consensus among 7 polled investment analysts is to Buy stock in Viking Therapeutics Inc. This rating has held steady since August, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.